Renaissance Technologies LLC grew its holdings in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 11.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,133,607 shares of the medical equipment provider’s stock after acquiring an additional 113,607 shares during the quarter. Renaissance Technologies LLC owned 2.96% of Lantheus worth $16,494,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of LNTH. Vaughan Nelson Investment Management L.P. purchased a new position in shares of Lantheus in the second quarter worth $21,246,000. BlackRock Inc. increased its stake in shares of Lantheus by 17.7% in the second quarter. BlackRock Inc. now owns 4,646,172 shares of the medical equipment provider’s stock worth $67,603,000 after buying an additional 700,248 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Lantheus by 208.2% in the second quarter. Russell Investments Group Ltd. now owns 618,775 shares of the medical equipment provider’s stock worth $9,004,000 after buying an additional 417,978 shares during the period. Boston Partners increased its stake in shares of Lantheus by 198.1% in the second quarter. Boston Partners now owns 356,790 shares of the medical equipment provider’s stock worth $5,191,000 after buying an additional 237,090 shares during the period. Finally, Bank of Montreal Can purchased a new position in shares of Lantheus in the second quarter worth $2,427,000. 92.52% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts recently commented on the stock. BidaskClub downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine raised shares of Lantheus from a “sell” rating to a “hold” rating in a research note on Monday, August 20th. Zacks Investment Research downgraded shares of Lantheus from a “hold” rating to a “sell” rating in a research note on Saturday, August 4th. Wells Fargo & Co decreased their target price on shares of Lantheus from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, August 2nd. Finally, Credit Suisse Group decreased their target price on shares of Lantheus from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Thursday, August 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $23.75.

NASDAQ:LNTH opened at $14.55 on Friday. The firm has a market capitalization of $570.67 million, a P/E ratio of 14.70, a P/E/G ratio of 3.43 and a beta of 1.30. Lantheus Holdings Inc has a twelve month low of $12.80 and a twelve month high of $24.45. The company has a current ratio of 3.86, a quick ratio of 3.14 and a debt-to-equity ratio of 5.94.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, August 1st. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.04. The business had revenue of $85.60 million for the quarter, compared to analysts’ expectations of $87.90 million. Lantheus had a net margin of 37.53% and a return on equity of 560.19%. The firm’s revenue for the quarter was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.35 earnings per share. analysts predict that Lantheus Holdings Inc will post 0.87 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.

Recommended Story: What is a Stop Order?

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.